Custom Compounded Tesamorelin Injection

Because this peptide requires a subcutaneous (under the skin) injection, ensuring complete aseptic purity is vital. Our compounding pharmacy prepares every batch of Tesamorelin in strict compliance with USP sterile compounding regulations within our certified cleanroom facility.

• Active Ingredient: High-purity Tesamorelin (formulated to mirror the clinical profile of the reference brand Egrifta®).
• Preparation Type: Sterile Injectable Solution (lyophilized powder for reconstitution).
• Administration Route: Subcutaneous injection.
• Quality Controls: Every single production lot undergoes rigorous safety evaluations, including mandatory sterile filtration validation, weight-checked potency verification, and endotoxin screening before patient delivery.

Tesamorelin acts as a highly selective agonist, meaning it binds to and activates a specific receptor to generate a therapeutic response. It works via the following endocrine stages:

• GHRH Receptor Binding: Once injected, Tesamorelin binds directly to GHRH receptors on the pituitary gland in the brain.
• Pulsatile Growth Hormone Release: This binding stimulates the pituitary to synthesize and release Growth Hormone (GH) in a natural, pulsed pattern.
• IGF-1 Stimulation: The released growth hormone travels to the liver, prompting the release of Insulin-like Growth Factor 1 (IGF-1).
• Lipolysis Activation: Increased systemic levels of GH and IGF-1 break down fat molecules, specifically reducing visceral fat cells around the stomach area while keeping peripheral subcutaneous fat intact.

Tesamorelin requires careful handling, strict adherence to sterile injection techniques, and routine clinical evaluation.

• Administration Method: Administered via daily subcutaneous injection into the abdomen, avoiding the belly button, scar tissue, or areas with bruising. Rotate your injection sites daily to minimize localized skin changes.
• Monitoring Requirements: Your physician will routinely monitor your IGF-1 levels and metabolic indicators. Because growth hormone can impact insulin sensitivity, blood sugar tracking is often recommended.
• Clinical Exclusions: Tesamorelin should not be used by pregnant individuals, those with an active malignancy, or patients with a history of disrupted pituitary gland function.
• Common Adaptations: Mild, temporary side effects can include localized redness or swelling at the injection site, minor muscle aches, or temporary fluid retention.

How does this compound compare to the brand-name Egrifta®?

Our compounded Tesamorelin contains the identical active peptide sequence found in Egrifta®. It works through the exact same metabolic pathways to reduce abdominal lipodystrophy, providing an alternative option that can be customized to your provider’s specific prescription demands.

How should this sterile peptide be stored?

Tesamorelin is highly sensitive to heat and environmental degradation. The unmixed lyophilized (freeze-dried) vials should be kept refrigerated or stored as directed by our pharmacy staff. Once reconstituted with the provided sterile diluent, the solution must be used immediately or refrigerated according to the specific pharmacy safety label.

Do you ship this medication outside the state of Texas?

No. To stay in complete alignment with the Texas State Board of Pharmacy licensing rules and federal distribution bounds, we fill, verify, and ship all sterile compounded Tesamorelin orders exclusively to patient addresses located inside the state of Texas.